<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2026.1741232</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>Odoribacter splanchnicus</italic> inhibits toxin production in <italic>Clostridioides difficile</italic>: insights from clinical correlation and <italic>in vitro</italic> validation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname> <given-names>Na</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3241322"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes"><name><surname>Fan</surname> <given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3347804"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author"><name><surname>Geng</surname> <given-names>Xianbo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3347816"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname> <given-names>Shujuan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3347817"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author"><name><surname>Pan</surname> <given-names>Zhaoyi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3273163"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Jin</surname> <given-names>Changzhong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname> <given-names>Yunbo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1378014"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
<contrib contrib-type="author"><name><surname>Wu</surname> <given-names>Nanping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Jinan Microecological Biomedicine Shandong Laboratory</institution>, <city>Jinan</city>, <country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine</institution>, <city>Hangzhou</city>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Changzhong Jin, <email xlink:href="mailto:jinchangzhong@jnl.ac.cn">jinchangzhong@jnl.ac.cn</email>; Yunbo Chen, <email xlink:href="mailto:chenyunbo@aliyun.com">chenyunbo@aliyun.com</email></corresp>
<fn fn-type="equal" id="fn0001">
<label>&#x2020;</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-22">
<day>22</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1741232</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Wang, Fan, Geng, Zhang, Pan, Jin, Chen and Wu.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Wang, Fan, Geng, Zhang, Pan, Jin, Chen and Wu</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-22">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p><italic>Clostridioides difficile</italic> infection (CDI) is a leading cause of healthcare-associated diarrhea. Although gut microbiota dysbiosis is central to CDI, the specific commensal species that confer protection are not well defined.</p>
</sec>
<sec>
<title>Methods</title>
<p>We performed 16S rRNA sequencing on fecal samples from a clinical cohort of 30 CDI patients, 30 non-CDI diarrhea patients, 27 asymptomatic <italic>C. difficile</italic> carriers, and 30 healthy controls. To functionally validate the clinical finding, an in vitro anaerobic co-culture system was established between the <italic>Odoribacter splanchnicus</italic> type strain and <italic>C. difficile</italic>. Toxin protein levels in the supernatant were quantified by ELISA at multiple time points (24, 48, and 72 h). Sporulation was assessed via ethanol resistance assays, and the expression of toxin genes (tcdA/tcdB) was measured by quantitative PCR (qPCR).</p>
</sec>
<sec>
<title>Results</title>
<p>Clinical analysis revealed a significant negative correlation between the abundance of Odoribacter splanchnicus and CDI severity. In vitro, a high initial ratio of <italic>O. splanchnicus</italic> significantly suppressed <italic>C. difficile</italic> toxin production during the stationary phase, without inhibiting bacterial growth. This reduction <italic>in vitro</italic> levels was accompanied by a concurrent increase in sporulation and was preceded by a downregulation of tcdB gene expression.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This work positions <italic>O. splanchnicus</italic> as a highly promising candidate for the development of next-generation, defined microbial therapeutics and provides a mechanistic foundation for future anti-virulence approaches to combat CDI.</p>
</sec>
</abstract>
<kwd-group>
<kwd>
<italic>Clostridioides difficile</italic>
</kwd>
<kwd>commensal bacteria</kwd>
<kwd>gut microbiome</kwd>
<kwd>
<italic>Odoribacter splanchnicus</italic>
</kwd>
<kwd>sporulation</kwd>
<kwd>toxin inhibition</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>the Shandong Provincial Laboratory Project</institution>
</institution-wrap>
</funding-source>
<award-id rid="sp1">SYS202202</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">
<institution-wrap>
<institution>the National Key R&#x0026;D Program of China</institution>
</institution-wrap>
</funding-source>
<award-id rid="sp2">2023YFC2506004</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">
<institution-wrap>
<institution>the Research Project of Jinan Microecological Biomedicine Shandong Laboratory</institution>
</institution-wrap>
</funding-source>
<award-id rid="sp3">JNL-2025004B</award-id>
<award-id rid="sp3">JNL-2025005B</award-id>
<award-id rid="sp3">JNL-2022001Q</award-id>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">
<institution-wrap>
<institution>Shandong Provincial Natural Science Foundation</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100007129</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp4">ZR2023QH494</award-id>
</award-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by Shandong Provincial Natural Science Foundation [grant number ZR2023QH494]; the Research Project of Jinan Microecological Biomedicine Shandong Laboratory [grant numbers JNL-2022001Q, JNL-2025005B, JNL-2025004B]; the National Key R&#x0026;D Program of China [2023YFC2506004]; and the Shandong Provincial Laboratory Project [grant number SYS202202].</funding-statement>
</funding-group>
<counts>
<fig-count count="9"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="56"/>
<page-count count="15"/>
<word-count count="9081"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Infectious Agents and Disease</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p><italic>Clostridioides difficile</italic> is a Gram-positive, spore-forming, obligate anaerobe that often residing in human gut, capable of causing <italic>C. difficile</italic> infection (CDI) upon dysbiosis of gut microbiome (<xref ref-type="bibr" rid="ref45">Smits et al., 2016</xref>; <xref ref-type="bibr" rid="ref24">Kordus et al., 2022</xref>). The pathogenesis and clinical severity of CDI are primarily driven by the production of two large clostridial toxins: Toxin A (TcdA) and Toxin B (TcdB) (<xref ref-type="bibr" rid="ref51">Voth and Ballard, 2005</xref>). These toxins are the primary virulence factors responsible for the hallmark symptoms of CDI including mild diarrhea, pseudomembranous colitis and toxic megacolon (<xref ref-type="bibr" rid="ref36">Ofosu, 2016</xref>). In the past decades, CDI has become the leading cause of nosocomial gastrointestinal infection, with incidence rates increasing worldwide, resulting in high morbidity and mortality especially among hospitalized patients (<xref ref-type="bibr" rid="ref13">Finn et al., 2021</xref>; <xref ref-type="bibr" rid="ref42">Schnizlein and Young, 2022</xref>).</p>
<p>The management of CDI remains a major clinical challenge, primarily due to the multidrug-resistant nature of the pathogen. Current first-line therapies still rely on antibiotics such as vancomycin, metronidazole, and fidaxomicin (<xref ref-type="bibr" rid="ref15">Gupta et al., 2018</xref>). However, after more than three decades of use, declining susceptibility to these agents has led to reduced cure rates and the emergence of multidrug-resistant strains (<xref ref-type="bibr" rid="ref2">Caballero et al., 2017</xref>). Moreover, antibiotics like vancomycin and metronidazole further disrupt the gut ecological balance, resulting in high recurrence rates of 25&#x2013;60% after initial treatment (<xref ref-type="bibr" rid="ref16">Henson, 2021</xref>). Given these limitations, non-antibiotic approaches&#x2014;particularly those targeting the microbiome&#x2014;have regained significant research interest. Fecal microbiota transplantation (FMT) has emerged as an effective intervention for recurrent and refractory CDI by restoring microbial diversity and colonization resistance (<xref ref-type="bibr" rid="ref21">Kelly et al., 2021</xref>; <xref ref-type="bibr" rid="ref22">Khoruts and Staley, 2025</xref>). Nevertheless, FMT carries potential risks, including the transfer of antibiotic resistance genes, inadvertent transmission of pathogens, bacterial translocation, and long-term metabolic complications (<xref ref-type="bibr" rid="ref18">Hudson et al., 2017</xref>; <xref ref-type="bibr" rid="ref7">DeFilipp et al., 2019</xref>; <xref ref-type="bibr" rid="ref8">DeLeon et al., 2025</xref>). One promising direction is developing defined microbial consortia or specific strains with known functions as an alternative to crude fecal suspensions, allowing more targeted and reproducible restoration of gut flora (<xref ref-type="bibr" rid="ref35">Murphy et al., 2023</xref>; <xref ref-type="bibr" rid="ref55">Yadegar et al., 2024</xref>). Given this, the identification of key commensal species that are directly associated with CDI progression, coupled with a mechanistic understanding of their function, is essential for guiding the development of targeted microbiota-based therapies.</p>
<p>Multiple studies have demonstrated that both community membership and abundance within the microbiota in patients with CDI are different from those of healthy individuals, including the lower richness and diversity, and decreased relative abundances of <italic>Faecalibacterium</italic>, <italic>Roseburia</italic>, <italic>Bifidobacterium</italic>, <italic>Blautia</italic>, Ruminococcaceae, Lachnospiraceae and other gut commensal members (<xref ref-type="bibr" rid="ref19">Kachrimanidou and Tsintarakis, 2020</xref>; <xref ref-type="bibr" rid="ref49">Vakili et al., 2020</xref>; <xref ref-type="bibr" rid="ref31">Martinez et al., 2022</xref>; <xref ref-type="bibr" rid="ref38">Piccioni et al., 2022</xref>). Nonetheless, targeted research aimed at identifying species directly linked to the clinical progression of CDI in patients remains scarce. Therefore, moving beyond general ecological observations to pinpoint clinically relevant species and delineate their precise functions has been of great significance to clinical applications.</p>
<p>In this study, we utilized 16S rRNA sequencing to characterize the gut microbiota alteration of hospitalized patients with or without CDI. Specifically, we focused on the asymptomatic colonization and CDI groups, aiming to identify the bacterial species whose abundance correlates with disease severity. Our analysis revealed that the abundance of <italic>Odoribacter splanchnicus</italic> exhibited a significant negative correlation with CDI severity. This bacterium is strictly anaerobic, Gram-negative, non-sporulating, known for its production of short-chain fatty acids (SCFAs), properties that make it a compelling candidate for development as a next-generation probiotic (<xref ref-type="bibr" rid="ref41">Sato et al., 2021</xref>; <xref ref-type="bibr" rid="ref25">Li et al., 2025</xref>). We demonstrate that <italic>O. splanchnicus</italic> directly suppresses the production of the key virulence factors, TcdA and TcdB, and exerts a multifaceted impact on the <italic>C. difficile</italic> life cycle, including its growth and sporulation by <italic>in vitro</italic> experiments. Our results may help to elucidate the protective role of commensal bacteria against <italic>C. difficile</italic> pathogenesis and pave the way for developing <italic>O. splanchnicus</italic>-based biotherapeutics for CDI treatment.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Study design and specimen collection</title>
<p>Our study enrolled 117 patients hospitalized at the First Affiliated Hospital, Zhejiang University School of Medicine (China), after informed consent. Considering patients were hospitalized for different causes and subsequently underwent different treatments, no exclusion criteria except minimum age of 18 was used in this study. Stool samples collected from these 117 patients were divided into four groups associated with diarrhea and <italic>C. difficile</italic> colonization statuses: (1) Control group (CN, <italic>n</italic>&#x202F;=&#x202F;30): patients without diarrhea symptoms and a negative <italic>C. difficile</italic> test by glutamate dehydrogenase (GDH), enzyme immunoassay (EIA) toxin A/B and quantitative PCR for toxin B gene. (2) Non-CDI diarrhea (NCD, <italic>n</italic>&#x202F;=&#x202F;30): patients with diarrhea (a passage of more than 3 times of unformed stools) and a negative <italic>C. difficile</italic> test same as the control group. (3) CDI group (CDI, <italic>n</italic>&#x202F;=&#x202F;30): patients diagnosed with new-onset diarrhea and a positive <italic>C. difficile</italic> test. (4) Asymptomatic colonization group (AC, <italic>n</italic>&#x202F;=&#x202F;27): patients without diarrhea and a positive <italic>C. difficile</italic> test. Diarrhea was defined as &#x2265;3 loose stools in 24&#x202F;h (<xref ref-type="bibr" rid="ref50">V&#x00E1;zquez-Cuesta et al., 2023</xref>). Patients who had CDI episodes or CDI treatment within the past 3&#x202F;months were excluded.</p>
<p>Stool samples were collected in sterile containers and immediately transported to the laboratory for CDI diagnosis, and then stored at &#x2212;80&#x202F;&#x00B0;C until DNA extraction.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Fecal DNA extraction and quantitative PCR for toxigenic <italic>Clostridioides difficile</italic></title>
<p>Stool DNA was extracted using the DNeasy PowerSoil Pro Kit (Qiagen, Germany) according to the manufacturer&#x2019;s instructions. DNA concentration and purity were measured using NanoDrop 2000 (Thermo Fisher Scientific, MA, United States).</p>
<p>Primer sequences used for toxigenic <italic>C. difficile</italic> quantification were F: 5&#x2019;-AGC AGTTGAATATAGTGGTTTAGTTAGAGTTG-3&#x2019;and R: 5&#x2019;-CATGCTTTTTTAGTTT CTGGATTGAA-3&#x2032; (<xref ref-type="bibr" rid="ref27">Maestri et al., 2022</xref>). Quantitative PCR (qPCR) was performed on a C1000-Touch Real-time PCR instrument (Bio-Rad, United States). The reaction system and conditions of qPCR were established by following the protocol of ChamQ SYBR qPCR Master Mix (Vazyme, China). All samples were performed in duplicate, and samples were considered positive when both replicates were positive.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Bacterial 16S rRNA sequencing and raw data processing</title>
<p>The hypervariable V3V4 region of bacterial 16S rRNA gene was amplified using 343F (5&#x2019;-TACGGRAGGCAGCAG-3&#x2032;) and 798R (5&#x2019;-AGGGTATCTAATCCT-3&#x2032;). Amplicons were tested by 2% agarose gel electrophoresis and purified with Agencourt AMPure XP beads (Beckman Coulter Co., United States). The purified DNA samples were sent for sequencing on Illumina NovaSeq6000 platform (Shanghai OE Biotech, China). Raw sequencing data were deposited in the China National Center for Bioinformation (CNCB) under accession number PRJCA050088.</p>
<p>The raw sequencing data were trimmed and filtered to obtain high-quality data (clean data). Then amplicon sequence variants (ASV) and the ASV abundance table were generated using DADA2 with the default parameters of QIIME2 (<xref ref-type="bibr" rid="ref4">Callahan et al., 2016</xref>). All ASVs were annotated and blasted against SILVA 138 database to obtain taxonomic classification.</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Bioinformatic analysis</title>
<p>The core microbiota of each group based on ASV level was identified here. The richness of gut bacterial communities in CN, NCD, CDI and AC groups were estimated by Chao1 index. Principal coordinates analysis (PCoA) was generated to assess bacterial community structure among different groups based on unweighted unifrac distances. Co-occurrence network analyses were performed using the Molecular Ecological Network Analyses (MENA, <ext-link xlink:href="http://ieg4.rccc.ou.edu/MENA/" ext-link-type="uri">http://ieg4.rccc.ou.edu/MENA/</ext-link>), and the network was visualized using Gephi 0.10.1 (<xref ref-type="bibr" rid="ref9">Deng et al., 2012</xref>). We use linear discriminant analysis (LDA) and LDA effective size analysis (LEfSe) to illustrate species difference at the level of genus between AC and CDI groups. Spearman&#x2019;s correlation analysis was applied to analyze the correlation between differential genus and disease severity. CDI severity score index was calculated in accordance with previous studies (<xref ref-type="bibr" rid="ref37">Peretz et al., 2016</xref>; <xref ref-type="bibr" rid="ref34">Mulki et al., 2017</xref>). For each patient the score incorporated nine parameters, each variable added one point: serum albumin &#x003C;3&#x202F;g/dL, a WBC count that is markedly high (&#x003E;50,000 cells/mL) or low (&#x003C;2000 cells/mL), serum creatinine &#x003E;130&#x202F;&#x03BC;mol/L, serum lactate levels &#x003E;2.2&#x202F;mmol/L, temperature &#x003E;38.5&#x202F;&#x00B0;C, systolic blood pressure &#x003C;100&#x202F;mmHg, altered mental status, severe abdominal tenderness or distention, intestinal symptoms such as ileus, obstruction, perforation, toxic mega-colon.</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>Bacteria strains and co-culture systems construction</title>
<p><italic>C. difficile</italic> strain (CD) used for co-culture was clinical isolate (sequencing type 54, <italic>tcdA</italic>+/<italic>tcdB</italic>+) that was preserved in our laboratory. <italic>O. splanchnicus</italic> strain ATCC 29572 (OS) was purchased from BeNa Culture Collection, Henan, China. CD and OS were grown at 37&#x202F;&#x00B0;C in brain-heart-infusion broth (Oxoid) supplemented with 0.5% yeast extract (Oxoid) and 0.1% L-cysteine (Sigma-Aldrich) (BHIS), under the anaerobic environment (80% nitrogen, 10% hydrogen, 10% carbon dioxide) (<xref ref-type="bibr" rid="ref44">Smith et al., 2022</xref>).</p>
<p>To construct co-culture systems, single colonies of CD and OS were separately inoculated into BHIS and grown anaerobically at 37&#x202F;&#x00B0;C overnight. Each strain was sub-cultured into fresh media and grown to mid-exponential phase (OD<sub>600nm</sub>&#x202F;=&#x202F;0.3 to 0.7). Then, the co-cultures of the two strains were prepared at different inoculation ratios (CD: OS&#x202F;=&#x202F;9:1, CD: OS&#x202F;=&#x202F;1:1, CD: OS&#x202F;=&#x202F;1:9), and the final inoculum concentration was 1&#x202F;&#x00D7;&#x202F;10<sup>7</sup>&#x202F;CFU/mL.</p>
</sec>
<sec id="sec8">
<label>2.6</label>
<title>Determination of co-culture proportions by species-specific qPCR</title>
<p>At each timepoint (6&#x202F;h,12&#x202F;h,18&#x202F;h,24&#x202F;h and 30&#x202F;h), 1&#x202F;mL samples of co-cultures were taken, centrifugated at 12000 g for 1&#x202F;min and the supernatant discarded. Cell pellets were frozen at &#x2212;80&#x202F;&#x00B0;C until gDNA extractions were performed. The gDNA was extracted using a DNeasy PowerSoil Pro Kit (Qiagen) as per the manufacturer&#x2019;s instructions. Primers specific to OS were designed based on the sequence of the hypervariable regions of 16S rRNA gene (F: 5&#x2032;- GTGGGTAGCGAACAGGATTAG-3&#x2032;; R: 5&#x2032;- CCCAGGTGGCTCACTTAATAC-3&#x2032;). Primers specific to CD and the qPCR reaction was performed as mentioned above. For absolute quantitation of copy numbers of CD and OS, a standard curve method was employed. Briefly, a fragment containing the target qPCR amplicon for each bacterium was amplified from genomic DNA using specific primers and cloned into a standard plasmid vector using a TA cloning kit (Promega, United States). The resulting recombinant plasmids were verified by sequencing. Plasmid DNA was extracted and quantified using a spectrophotometer. The copy number of each plasmid per microliter was calculated and a ten-fold serial dilution series of each plasmid was prepared to generate the standard curve. The amplification efficiency was 105.9%, <italic>R</italic><sup>2</sup> =&#x202F;0.9995 for OS primers and 107.8%, <italic>R</italic><sup>2</sup> =&#x202F;0.9979 for CD primers (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref>). The copy numbers of CD and OS in each experimental sample were then interpolated from their respective standard curves.</p>
</sec>
<sec id="sec9">
<label>2.7</label>
<title>Detection of toxin production in co-cultures by ELISA</title>
<p>Toxin production was monitored over time by collecting culture supernatants at 12-, 24-, 48-, and 72-h post-inoculation. Toxins (both TcdA and TcdB) concentrations in co-cultures were determined using ELISA kit (tgcBiomics, Germany). The blank media used for culturing was set as negative control, and supernatant of CD monocultures was set as positive control (<xref ref-type="bibr" rid="ref47">Sulaiman et al., 2024</xref>).</p>
</sec>
<sec id="sec10">
<label>2.8</label>
<title>Relative quantification of <italic>tcdA</italic> and <italic>tcdB</italic> expression</title>
<p>For gene expression analysis, 1&#x202F;mL aliquots of the co-culture were harvested at 12, 24, 48, and 72&#x202F;h. Bacterial cells were pelleted by centrifugation at 12,000 g for 1&#x202F;min. Total RNA was then extracted from the pellet using the RNeasy mini kit (Qiagen, Germany) with on-column DNase I digestion to eliminate genomic DNA contamination. The isolated total RNA was reverse transcribed by PrimeScript&#x2122;RT Master Mix (Takara, Japan) according to manufacturer&#x2019;s instructions. A 7500 real-time PCR system (Bio-Rad, United States) was used to perform quantitative PCR reactions. The system and conditions of RT-qPCR were established by following the protocol of the SYBR<sup>&#x00AE;</sup> Premix Ex Taq Kit (Takara, Japan). Primer sequences used for <italic>tcdA</italic> quantification were tcdA-F: 5&#x2019;-GCGGAAATGGTAGAAATG-3&#x2032; and tcdA-R: 5&#x2019;-ATCAGGTGCTATCAATACTT-3&#x2032; (<xref ref-type="bibr" rid="ref56">Zhu et al., 2021</xref>). Primer sequences used for <italic>tcdB</italic> quantification were F: 5&#x2019;-AGC AGTTGAATATAGTGGTTTAGTTAGAGTTG-3&#x2019;and R: 5&#x2019;-CATGCTTTTTTAGTTT CTGGATTGAA-3&#x2032; (<xref ref-type="bibr" rid="ref27">Maestri et al., 2022</xref>). 16&#x202F;s rRNA of <italic>C. difficile</italic> used as an internal control, primer sequences were CD16-F: 5&#x2019;-TTGAGCGATTTACTTCGGTAAAGA-3&#x2032; and CD16-R: 5&#x2019;-CCATCCTGTACTGGCTCACCT-3&#x2032;. Relative gene transcript levels was calculated by the 2<sup>&#x2212;&#x0394;&#x0394;CT</sup> method (<xref ref-type="bibr" rid="ref26">Livak and Schmittgen, 2001</xref>). All reactions were carried out in triplicate.</p>
</sec>
<sec id="sec11">
<label>2.9</label>
<title>Cytotoxicity assay</title>
<p>Cytotoxicity assays were done on Vero cells (<xref ref-type="bibr" rid="ref48">Trzilova et al., 2022</xref>). For the assay, Vero cells were passaged in a 96-multiwell plate and incubated for 24&#x202F;h prior to use. Cells were seeded in a six-well plate (3&#x202F;&#x00D7;&#x202F;10<sup>5</sup> cells/well), in Dulbecco&#x2019;s Modified Eagles Medium (DMEM), supplemented with 10% fetal bovine serum. Cells were grown for 24&#x202F;h at 37&#x202F;&#x00B0;C, 5% CO<sub>2</sub> in air atmosphere. Supernatants collected at various time points were centrifuged and filtered through a 0.22&#x202F;&#x03BC;m filter. 50&#x202F;&#x03BC;L of the final content was added to each well plate and plates were incubated at 37&#x202F;&#x00B0;C, in 5% CO<sub>2</sub>, for 18&#x202F;h. Empty BHIS medium served as negative control. Cell rounding was assessed using a 10x objective on a light microscope.</p>
</sec>
<sec id="sec12">
<label>2.10</label>
<title>Ethanol resistance sporulation assay</title>
<p>Ethanol resistance was used to determine the sporulation efficiency of monoculture and co-culture systems based on previously described procedures (<xref ref-type="bibr" rid="ref12">Edwards and McBride, 2014</xref>; <xref ref-type="bibr" rid="ref11">Donnelly et al., 2022</xref>). 0.5&#x202F;mL aliquot of culture was mixed with 0.5&#x202F;mL 95% ethanol, subjected to vortex mixing, incubated at room temperature for 15&#x202F;min, serially diluted in 1&#x202F;&#x00D7;&#x202F;PBS, and plated on BHIS with 0.1% taurocholate to enumerate spores.</p>
</sec>
<sec id="sec13">
<label>2.11</label>
<title>Statistical analyses</title>
<p>Our monoculture and co-culture growth contain 3 biological replicates, data are expressed as mean &#x00B1; SEM. Statistical analysis among multiple groups was performed using SPSS (24.0) for one-way ANOVA analysis, and statistical significance was set at <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05. These results were visualized Origin 2024 software.</p>
</sec>
</sec>
<sec sec-type="results" id="sec14">
<label>3</label>
<title>Results</title>
<sec id="sec15">
<label>3.1</label>
<title>Participant characteristics</title>
<p>The 117 patients included in our study were divided into the control group (CN, 30 subjects), non-CDI diarrhea group (NCD, 30 subjects), CDI group (CDI, 30 subjects) and asymptomatic carrier group (AC, 27 subjects). The patients&#x2019; characteristics are presented in <xref ref-type="table" rid="tab1">Table 1</xref>. The median age of all group patients was around of 60&#x202F;years, and the majority of AC and CDI groups were long stay inpatients (over 30&#x202F;days). There were no significant differences in the rate of use of antibiotics among groups (<italic>p</italic>&#x202F;=&#x202F;0.348).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Characteristics of patients.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>Characteristics</th>
<th align="center" valign="top">CN (<italic>n</italic> =&#x202F;30)</th>
<th align="center" valign="top">NCD (<italic>n</italic> =&#x202F;30)</th>
<th align="center" valign="top">CDI (<italic>n</italic> =&#x202F;30)</th>
<th align="center" valign="top">AC (<italic>n</italic> =&#x202F;27)</th>
<th align="center" valign="top">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle" colspan="6">Age</td>
</tr>
<tr>
<td align="left" valign="middle">Mean &#x00B1; SD</td>
<td align="center" valign="middle">59.33&#x202F;&#x00B1;&#x202F;16.86</td>
<td align="center" valign="middle">58.73&#x202F;&#x00B1;&#x202F;13.56</td>
<td align="center" valign="middle">63.77&#x202F;&#x00B1;&#x202F;17.04</td>
<td align="center" valign="top">65.33&#x202F;&#x00B1;&#x202F;18.48</td>
<td align="center" valign="top">0.345</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="6">Sex</td>
</tr>
<tr>
<td align="left" valign="middle">Female</td>
<td align="center" valign="middle">11 (36.7%)</td>
<td align="center" valign="middle">15 (50%)</td>
<td align="center" valign="middle">9 (30%)</td>
<td align="center" valign="top">12 (44.4%)</td>
<td align="center" valign="top">0.458</td>
</tr>
<tr>
<td align="left" valign="middle">Male</td>
<td align="center" valign="middle">19 (63.3%)</td>
<td align="center" valign="middle">15 (50%)</td>
<td align="center" valign="middle">21 (70%)</td>
<td align="center" valign="top">15 (55.6%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle" colspan="6">Hospital stays</td>
</tr>
<tr>
<td align="left" valign="middle">&#x2264;30</td>
<td align="center" valign="top">9 (30%)</td>
<td align="center" valign="top">18 (60%)</td>
<td align="center" valign="top">4 (13.3%)</td>
<td align="center" valign="top">6 (22.2%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x003E;30 &#x0336; &#x2264;60</td>
<td align="center" valign="top">1 (3.3%)</td>
<td align="center" valign="top">5 (16.7%)</td>
<td align="center" valign="top">7 (23.3%)</td>
<td align="center" valign="top">3 (11.1%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x003E;60 &#x0336; &#x2264;90</td>
<td align="center" valign="top">7 (23.3%)</td>
<td align="center" valign="top">1 (3.3%)</td>
<td align="center" valign="top">4 (13.3%)</td>
<td align="center" valign="top">3 (11.1%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">&#x003E;90</td>
<td align="center" valign="top">13 (43.3%)</td>
<td align="center" valign="top">6 (20%)</td>
<td align="center" valign="top">15 (50%)</td>
<td align="center" valign="top">15 (55.6%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle" colspan="6">Ward at stool collection</td>
</tr>
<tr>
<td align="left" valign="middle">With cancer</td>
<td align="center" valign="middle">3 (10%)</td>
<td align="center" valign="middle">7 (23.3%)</td>
<td align="center" valign="middle">6 (20%)</td>
<td align="center" valign="middle">4 (14.8%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">With hematopathy</td>
<td align="center" valign="middle">10 (33.3%)</td>
<td align="center" valign="middle">4 (13.3%)</td>
<td align="center" valign="middle">1 (3.3%)</td>
<td align="center" valign="middle">5 (16.7%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">With respiration failure</td>
<td align="center" valign="middle">2 (6.7%)</td>
<td align="center" valign="middle">0 (0%)</td>
<td align="center" valign="middle">1 (3.3%)</td>
<td align="center" valign="middle">2 (7.4%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">With renal insufficiency</td>
<td align="center" valign="middle">1 (3.3%)</td>
<td align="center" valign="middle">0 (0%)</td>
<td align="center" valign="middle">4 (13.3%)</td>
<td align="center" valign="middle">0 (0%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle" colspan="6">Antibiotics usage</td>
</tr>
<tr>
<td align="left" valign="middle">Yes</td>
<td align="center" valign="middle">26 (86.7%)</td>
<td align="center" valign="middle">21 (70%)</td>
<td align="center" valign="middle">21 (70%)</td>
<td align="center" valign="middle">23 (85.2%)</td>
<td align="center" valign="top">0.348</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec16">
<label>3.2</label>
<title>Bacterial community structure analysis</title>
<p>In total, 2,879 ASVs were obtained from the 117 fecal samples, and the number of ASVs of each sample ranged from 25 to 258. According to previous studies, the ASVs that presented in all groups were defined as core taxa, the ASVs that only presented in one group were defined as unique taxa, and the ASVs shared by two or three groups were defined as other taxa (<xref ref-type="bibr" rid="ref43">Shade and Handelsman, 2012</xref>). As shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, the numbers of total ASVs were similar between CN (1,250 ASVs) and AC (1,206 ASVs) groups, while the total ASV numbers of NCD (1,077 ASVs) and CDI (1,071 ASVs) groups were very close. The number of ASVs that were shared by all groups was 264, and the four groups had large proportion of unique ASVs, and the number of unique ASVs was highest in AC (511 ASVs), followed by CN (493 ASVs), CDI (466 ASVs) and NCD (460 ASVs). The shared ASVs in CN&#x0026;AC were highest (126 ASVs), followed by CN&#x0026;AC&#x0026;NCD (97 ASVs). The <italic>&#x03B1;</italic>-diversity analysis suggested that the microbial diversity was significantly decreased in CDI and AC groups, compared to CN group (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Furthermore, <italic>&#x03B2;</italic>-diversity analysis indicated that the composition of bacterial communities in CDI group significantly differed from other groups (PERMANOVA, <italic>p</italic>&#x202F;=&#x202F;0.001), while CN, NCD and AC groups had similar microbial community structure (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Altogether, these findings indicated patients with true infection had unique gut microbial community, and the gut microbiome may be a potential biomarker source.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Biodiversity of gut microbiota from CN, NCD, CDI and AC groups. <bold>(A)</bold> Upset plot showing shared and unique ASVs of CN, NCD, AC and CDI groups. Calculations are based on ASV abundance table. <bold>(B)</bold> &#x03B1;-diversity comparison between the groups via Chao index analysis. &#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, &#x002A;&#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.01. <bold>(C)</bold> <italic>&#x03B2;</italic>-diversity comparison via unweighted UniFrac distances PCoA analysis.</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">(A) Bar chart and dot matrix showing ASV intersections across four groups: CDI, NCD, AC, and CN. The highest intersection size is 511. (B) Box plot comparing Chao1 diversity index for CN, NCD, CDI, and AC. Statistically significant differences are marked. (C) PCoA plot displaying microbial community composition across four groups with ellipses representing group dispersion.</alt-text>
</graphic>
</fig>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Bar plot of the taxonomic composition of the microbial community at the phylum level <bold>(A)</bold> and genus level <bold>(B)</bold> for CN, NCD, CDI and AC groups.</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Bar charts (A) and (B) show the relative abundance of bacterial groups across four conditions: CN, NCD, CDI, and AC. Chart (A) categorizes bacteria into Firmicutes, Proteobacteria, Bacteroidota, Actinobacteriota, and others. Chart (B) further breaks down bacteria types, including Enterococcus, Escherichia, and others. Both charts illustrate varied bacterial composition across conditions.</alt-text>
</graphic>
</fig>
<p>To further understand the bacterial composition differences among CN, NCD, CDI and AC groups, we analyzed the relative abundance of fecal microbes in each group at phylum and genus level, respectively. Generally, the phylum Firmicutes displayed the highest relative abundance in all groups (CN, 61.8%; NCD, 51.3%; CDI, 56.5%; AC, 54.7%) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The phylum Proteobacteria was increased in CDI (27.0%), AC (27.0%), and especially in NCD (38.8%) compared to CN (22.2%). In addition, CDI and AC group had increased Bacteroidota and decreased Actinobacteriota at phylum level compared to CN and NCD groups. Moreover, the differences among groups at the genus level (top 10 in abundance) were further investigated. As shown in <xref ref-type="fig" rid="fig2">Figure 2B</xref>, the relative abundance of <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> decreased in NCD, CDI and AC groups, while the relative abundance of <italic>Escherichia</italic>, <italic>Klebsiella</italic> and <italic>Streptococcus</italic> increased in comparison with CN group.</p>
</sec>
<sec id="sec17">
<label>3.3</label>
<title>Microbial correlation network analysis</title>
<p>Furthermore, microbial co-occurrence network was constructed on genus level (&#x003E;0.1% relative abundance) to show the interactions among individual species. The network analysis results highlighted the differences of interaction properties between the four groups (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In comparison with CN (119 nodes, 398 edges), NCD (99 nodes, 292 edges) and CDI (88 nodes, 170 edges) had lower number of nodes and edges. Moreover, NCD and CDI also showed the decreasing average degree and lower proportion of negative interactions, indicating weaker bacterial interactions in these two groups. AC (117 nodes, 426 edges) had more edges and higher average degree, however, the proportion of negative interactions decreased in AC in comparison with CN. CDI had distinct network structure compared to the other groups, shown with lower number of nodes and edges, decreased average degree and higher modularity (<xref ref-type="table" rid="tab2">Table 2</xref>). These results suggested that the bacterial interactions were much weaker in CDI group.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Genus co-occurrence networks of four groups based on Spearman correlation analysis. <bold>(A)</bold> CN group. <bold>(B)</bold> NCD group. <bold>(C)</bold> AC group. <bold>(D)</bold> CDI group. Each node represents a bacterial genus. The node size represents the relative abundance of each genus and the node color signifies the phylum with which the genus was affiliated. The red and blue lines refer to the Spearman coefficient, indicating positive and negative interactions between the nodes, respectively. Only high the high-confidence interactions (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.05) with high absolute correlation coefficients (&#x003E;0.63) were presented.</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Network diagrams labeled A, B, C, and D depict interactions among bacterial phyla. Nodes represent different phyla such as Firmicutes, Proteobacteria, and Bacteroidota, with varying sizes. Lines indicate positive (red) and negative (blue) interactions. The key at the bottom identifies node colors corresponding to each bacterial phylum.</alt-text>
</graphic>
</fig>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>The topological features of co-occurrence networks associated with different groups.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Network indexes</th>
<th align="center" valign="top">CN</th>
<th align="center" valign="top">NCD</th>
<th align="center" valign="top">AC</th>
<th align="center" valign="top">CDI</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Total nodes</td>
<td align="center" valign="middle">119</td>
<td align="center" valign="middle">99</td>
<td align="center" valign="middle">117</td>
<td align="center" valign="middle">88</td>
</tr>
<tr>
<td align="left" valign="middle">Total links</td>
<td align="center" valign="middle">398</td>
<td align="center" valign="middle">292</td>
<td align="center" valign="middle">426</td>
<td align="center" valign="middle">170</td>
</tr>
<tr>
<td align="left" valign="middle">Average degree (avgK)</td>
<td align="center" valign="middle">6.689</td>
<td align="center" valign="middle">5.899</td>
<td align="center" valign="middle">7.282</td>
<td align="center" valign="middle">3.864</td>
</tr>
<tr>
<td align="left" valign="middle">Average clustering coefficient (avgCC)</td>
<td align="center" valign="middle">0.133</td>
<td align="center" valign="middle">0.173</td>
<td align="center" valign="middle">0.113</td>
<td align="center" valign="middle">0.053</td>
</tr>
<tr>
<td align="left" valign="middle">Average path distance (GD)</td>
<td align="center" valign="middle">3.213</td>
<td align="center" valign="middle">3.063</td>
<td align="center" valign="middle">3.226</td>
<td align="center" valign="middle">3.754</td>
</tr>
<tr>
<td align="left" valign="middle">Modularity</td>
<td align="center" valign="middle">0.51</td>
<td align="center" valign="middle">0.487</td>
<td align="center" valign="middle">0.404</td>
<td align="center" valign="middle">0.538</td>
</tr>
<tr>
<td align="left" valign="middle">Negative links</td>
<td align="center" valign="middle">286</td>
<td align="center" valign="middle">191</td>
<td align="center" valign="middle">246</td>
<td align="center" valign="middle">94</td>
</tr>
<tr>
<td align="left" valign="middle">Positive links</td>
<td align="center" valign="middle">112</td>
<td align="center" valign="middle">101</td>
<td align="center" valign="middle">180</td>
<td align="center" valign="middle">76</td>
</tr>
<tr>
<td align="left" valign="middle">Negative links/Total links</td>
<td align="center" valign="middle">0.719</td>
<td align="center" valign="middle">0.654</td>
<td align="center" valign="middle">0.577</td>
<td align="center" valign="middle">0.553</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec18">
<label>3.4</label>
<title>Biomarker identification and assessment</title>
<p>Bacterial community structure and network analysis had suggested the significant gut microbiota alteration in CDI patients. To explore the biomarkers that could distinguish the true infection from asymptomatic colonization, we explored the most discriminative bacteria between AC and CDI groups using LefSe analysis. The cladogram indicated 76 discriminative features between AC and CDI groups (LDA score &#x2265; 2, <xref ref-type="fig" rid="fig4">Figure 4</xref>). Some known and potential probiotics including <italic>Bifidobacterium</italic>, <italic>Faecalibaculum</italic> and <italic>Odoribacter</italic> were significantly decreased in CDI group, while <italic>Dialister</italic>, <italic>Pasteurella</italic>, <italic>Pseudomonas</italic> and Veillonellaceae were enriched in CDI group.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>The cladogram of LEfSe analysis from phylum to genus between CDI and AC (LDA score &#x003E; 2).</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Phylogenetic tree diagram illustrating bacterial groups with a color-coded system. Clades are marked in red representing CDI and blue representing AC. Yellow nodes connect various branches. On the right, a legend identifies bacterial names corresponding to alphanumeric labels on the tree.</alt-text>
</graphic>
</fig>
<p>Next, all CDI patients were evaluated for the severity of the disease according to the criteria described above (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S2</xref>), and genera associated with CDI disease severity were analyzed. In total, 46 genera were significantly associated with severity scores, of which 14 were positively correlated with severity scores and 32 were negatively correlated with severity scores (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Among them, <italic>Odoribacter</italic> was the most negatively correlated with CDI severity scores, suggesting it&#x2019;s abundance may correlate with CDI disease progression. Subsequently, the abundance of <italic>Odoribacter</italic> among four groups was analyzed. Concordantly, we found that the abundance of <italic>Odoribacter</italic> was significantly lower in CDI group compared with CN, NCD and AC group (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p><bold>(A)</bold> Correlation analysis of discriminative genus and CDI severity. Red represents a positive correlation, blue represents a negative correlation, and only significant correlations (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.05) were shown here. <bold>(B)</bold> Relative abundance of <italic>Odoribacter</italic> in CN, NCD, AC and CDI groups (The same letter represents no significant difference between the groups, different letters represent significant differences (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.05) between the groups).</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g005.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Panel A displays a circular heatmap illustrating the correlation of various bacterial genera, with colors ranging from red to blue indicating a Spearman's Rho from positive to negative. Panel B shows a box plot comparing the relative abundance of bacteria across four groups: CN, NCD, AC, and CDI, with significant differences observed between CDI and the other groups, highlighted by different letters.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec19">
<label>3.5</label>
<title><italic>Odoribacter</italic> and <italic>Clostridioides difficile</italic> interactions in co-culture systems</title>
<p>To determine whether <italic>Odoribacter</italic> influences key pathogenesis phenotypes of <italic>C. difficile</italic> (CD) including bacterial growth, sporulation, and toxin production, we selected the type strain <italic>O. splanchnicus</italic> ATCC 29572 (OS) and established CD-OS co-culture systems with different bacterial concentration ratio and quantified the proportions of the two strains. We first determined the growth kinetics of CD and OS in monoculture. The growth curve of OS was characterized by a prolonged lag phase compared with CD (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). And we noticed the optical density of CD cultures began a sustained decrease after 12&#x202F;h, which might be indicative of the initiation of sporulation. The results of co-culture systems showed that OS bacterial load finally stabilized at 5&#x202F;&#x00D7;&#x202F;10<sup>8</sup>&#x202F;CFU/mL across all co-culture systems. However, the final bacterial load of <italic>C. difficile</italic> exhibited a significant reduction specifically in the 1:9 (CD: OS) ratio system (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). In contrast, the CD load remained stable at around 7&#x202F;&#x00D7;&#x202F;10<sup>7</sup>&#x202F;CFU/mL in the 1:1 and 9:1 ratio systems (<xref ref-type="fig" rid="fig6">Figures 6C</xref>,<xref ref-type="fig" rid="fig6">D</xref>). The shifting compositional ratio of the two species over time was also evaluated. The data show that the proportion of CD increased progressively until 18&#x202F;h, after which it underwent a consistent decrease. This reversal ultimately resulted in the dominance of OS in all systems at 30&#x202F;h (<xref ref-type="fig" rid="fig6">Figures 6B</xref>&#x2013;<xref ref-type="fig" rid="fig6">D</xref>).</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p><bold>(A)</bold> Growth curves of CD and OS in monoculture. <bold>(B)</bold> Co-culture of CD and OS in the 1:9 ratio system. Bacteria load (left Y axis, line chart) and proportions of the two species (right Y axis, bar graph). <bold>(C)</bold> Co-culture of CD and OS in the 1:1 ratio system. <bold>(D)</bold> Co-culture of CD and OS in the 9:1 ratio system. Absolute quantitation for CD and OS were calculated from an absolute standard curve method using the plasmid template for each target gene. Values represent the mean of three biological replicates. Error bars represent the mean&#x202F;&#x00B1;&#x202F;SEM of three biological replicates.</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g006.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Four graphs labeled A, B, C, and D depict bacterial growth and relative abundance over time. Graph A shows optical density, indicating growth trends for OS and CD. Graphs B, C, and D display bacterial counts in CFU per milliliter and relative abundance percentages, with OS and CD represented by different colors. Data points in all graphs include error bars for variability. Time is measured in hours, ranging from zero to thirty.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec20">
<label>3.6</label>
<title><italic>Odoribacter</italic> inhibit toxin production of <italic>Clostridioides difficile</italic> at high concentration</title>
<p>We next investigated the impact of OS on toxin production by CD. A time-course analysis of toxin levels in culture supernatants was performed by ELISA. At the 12-h time point, toxin accumulation was not detectable in any culture group, with levels falling below the assay&#x2019;s detection limit (data not shown). By 24&#x202F;h, toxins were detected in the CD monoculture and the CD: OS =&#x202F;9:1 co-culture, while it remained undetectable in the CD: OS =&#x202F;1:1 and 1:9 groups (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). A significant difference emerged at 48&#x202F;h, where the toxin titer in the CD monoculture reached approximately 8&#x202F;&#x03BC;g/L, which was significantly higher than in all co-culture conditions (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). At 72&#x202F;h, only the CD: OS =&#x202F;1:9 co-culture maintained a statistically significant reduction in toxin levels compared to the CD monoculture. The toxin levels in the CD: OS =&#x202F;9:1 and 1:1 groups, although numerically lower, were not significantly different from the monoculture control (<xref ref-type="fig" rid="fig7">Figure 7C</xref>).</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p>TcdA/TcdB production and <italic>tcdA</italic>/<italic>tcdB</italic> gene expression in CD monoculture and CD-OS co-cultures at different time points. <bold>(A)</bold> TcdA/TcdB production at 24&#x202F;h. <bold>(B)</bold> TcdA/TcdB production at 48&#x202F;h. <bold>(C)</bold> TcdA/TcdB production at 72&#x202F;h. <bold>(D)</bold> Relative gene expression of <italic>tcdA</italic> at 12, 24, 48 and 72&#x202F;h. <bold>(E)</bold> Relative gene expression of <italic>tcdB</italic> at 12, 24, 48 and 72&#x202F;h. The relative quantitative gene expression was calculated with the use of 2<sup>&#x2212;&#x0394;&#x0394;CT</sup> method. The relative expression levels of <italic>tcdA/B</italic> gene in CD monoculture were normalized to 1, with the 16S rDNA of CD used as an internal reference. All data were represented as mean &#x00B1; SEM (<italic>n</italic>&#x202F;=&#x202F;3). &#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, &#x002A;&#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.01, &#x002A;&#x002A;&#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001.</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g007.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Graphs depicting Toxin A+B levels and gene expression. (A-C) Bar charts show Toxin A+B in different CD/OS ratios, with significance markers. (D-E) Bar charts depict tcdA and tcdB gene expression over time at various ratios, with significant differences indicated.</alt-text>
</graphic>
</fig>
<p>To elucidate the molecular mechanism underlying this suppression, we quantified the expression of the toxin genes <italic>tcdA</italic> and <italic>tcdB</italic> via qPCR at corresponding time points. At the early 12-h time point, the expression of both <italic>tcdA</italic> and <italic>tcdB</italic> was significantly lower in all co-culture groups compared to the CD monoculture (<xref ref-type="fig" rid="fig7">Figures 7D</xref>,<xref ref-type="fig" rid="fig7">E</xref>). At subsequent time points, <italic>tcdA</italic> expression in co-cultures showed no significant difference from the monoculture. In contrast, a sustained transcriptional repression of <italic>tcdB</italic> was observed specifically in the CD: OS =&#x202F;1:9 and 1:1 co-cultures at 24&#x202F;h, where its expression remained significantly suppressed compared to the CD-alone control.</p>
<p>To validate that functional toxin was being released, a Vero cell cytotoxicity assay was performed using culture supernatants harvested at 12, 24, 48, and 72&#x202F;h. Morphological analysis revealed a clear time-dependent and co-culture-dependent cytopathic effect (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Supernatants from the 12-h time point, including that from the CD monoculture, induced no apparent morphological changes in Vero cells compared to the negative control. Exposure to 24-h supernatants resulted in initial cell rounding, which was markedly more severe in cells treated with the CD monoculture supernatant than in those treated with co-culture supernatants (CD: OS =&#x202F;9:1, 1:1, and 1:9), where a greater proportion of cells remained adherent. Treatment with 48-h and, particularly, 72-h supernatants led to extensive cell rounding and detachment. Notably, cells exposed to the 72-h supernatant from the CD monoculture showed substantial death. Across these later time points, the cytopathic effect was consistently mildest in cells treated with the supernatant from the CD: OS =&#x202F;1:9 co-culture.</p>
<fig position="float" id="fig8">
<label>Figure 8</label>
<caption>
<p>Cytopathic effects of co-culture supernatants collected from different time points on Vero cells. Each column represents a different group (from left to right, CD monoculture, CD/OS&#x202F;=&#x202F;1:9, CD/OS&#x202F;=&#x202F;1:1, CD/OS&#x202F;=&#x202F;9:1). Each row represents a different time point (from up to down, 12&#x202F;h, 24&#x202F;h, 48&#x202F;h, 72&#x202F;h). Vero cells treated with empty BHIS medium were used as negative control, cells treated with supernatants from CD monoculture were used as positive control. Experiments were performed in triplicate and representative pictures were shown. Scale bar: 100&#x202F;&#x03BC;m.</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g008.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Microscopic images showing cell cultures under different conditions (CD, CD/OS=1:9, CD/OS=1:1, CD/OS=9:1) at 12, 24, 48, and 72 hours. The bottom row shows the negative control. Each image includes a scale bar of 100 micrometers.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec21">
<label>3.7</label>
<title><italic>Odoribacter</italic> promotes sporulation of <italic>Clostridioides difficile</italic> at earlier stage</title>
<p>We further assessed the dynamics of CD spore formation under different co-culture conditions. Utilizing the ethanol tolerance of spores, we collected cultures at various time points, and quantified viable spores by plate counting. The results indicated that no significant spore formation was detected in any group at the early 12-h time point (<xref ref-type="fig" rid="fig9">Figures 9A</xref>,<xref ref-type="fig" rid="fig9">E</xref>). Although trace spores were observed in some replicates of the CD: OS =&#x202F;1:9 group, the high variability between biological replicates precluded statistical significance. By 24&#x202F;h, the spore counts in all co-culture groups (CD: OS =&#x202F;9:1, 1:1, and 1:9) were significantly higher than in the CD monoculture (<xref ref-type="fig" rid="fig9">Figures 9B</xref>,<xref ref-type="fig" rid="fig9">F</xref>). At the subsequent 48-h and 72-h time points, total spore numbers increased across all groups, with the CD: OS =&#x202F;1:9 co-culture consistently yielding the highest spore count (<xref ref-type="fig" rid="fig9">Figures 9C</xref>,<xref ref-type="fig" rid="fig9">D</xref>,<xref ref-type="fig" rid="fig9">G</xref>,<xref ref-type="fig" rid="fig9">H</xref>).</p>
<fig position="float" id="fig9">
<label>Figure 9</label>
<caption>
<p>Spore quantification of CD monoculture and CD-OS co-cultures at different time points. <bold>(A&#x2013;D)</bold> Colony-forming units (CFU) for spore quantification of CD monoculture and CD-OS co-cultures at 12, 24, 48 and 72&#x202F;h, respectively. Each group was serially diluted in a 10-fold gradient, 1&#x202F;&#x03BC;L of each dilution were spotted onto BHIS agar plates (supplemented with 0.1% taurocholate) and incubated anaerobically at 37&#x202F;&#x00B0;C. Representative pictures were shown. <bold>(E&#x2013;H)</bold> Statistics for spore production of CD monoculture and CD-OS co-cultures at different time points. All data were represented as mean &#x00B1; SEM (<italic>n</italic>&#x202F;=&#x202F;3). &#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, &#x002A;&#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.01.</p>
</caption>
<graphic xlink:href="fmicb-17-1741232-g009.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Panels (A) to (D) show images of bacterial colonies with increasing density from 10^0 to 10^3. Panels (E) to (H) are bar charts showing spore concentration in Log10 CFU/mL for different CD/OS ratios: CD, CD/OS=1:9, CD/OS=1:1, and CD/OS=9:1. Significant differences are indicated with asterisks in panels (F) and (G).</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec22">
<label>4</label>
<title>Discussion</title>
<p>The association between gut microbiota dysbiosis and <italic>Clostridioides difficile</italic> infection (CDI) is well-established. Consistent with prior research, we also found CDI patients exhibited a marked reduction in species richness and the lowest <italic>&#x03B1;</italic>-diversity indices compared to non-infection people with or without <italic>C. difficile</italic> colonization (<xref ref-type="bibr" rid="ref52">Wan et al., 2022</xref>; <xref ref-type="bibr" rid="ref53">Wei et al., 2022</xref>; <xref ref-type="bibr" rid="ref50">V&#x00E1;zquez-Cuesta et al., 2023</xref>). Furthermore, <italic>&#x03B2;</italic>-diversity and co-occurrence network analysis confirmed that the overall microbial community structure of the CDI group was significantly distinct from the other three groups, indicating a distinct microbial architecture associated with infection (<xref ref-type="bibr" rid="ref20">Ke et al., 2021</xref>). In line with the previous studies (<xref ref-type="bibr" rid="ref17">Herrera et al., 2022</xref>; <xref ref-type="bibr" rid="ref28">Mahnic et al., 2022</xref>), the relative abundance of potential probiotics such as <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> decreased in CDI, while the relative abundance of <italic>Escherichia</italic>, <italic>Klebsiella</italic> increased.</p>
<p>Previous studies have demonstrated that <italic>C. difficile</italic> colonization can alter the gut microbiota (<xref ref-type="bibr" rid="ref5">Couturier et al., 2022</xref>; <xref ref-type="bibr" rid="ref50">V&#x00E1;zquez-Cuesta et al., 2023</xref>), therefore, to identify species which are not merely associated with the presence of <italic>C. difficile</italic>, but specifically linked to the critical transition from colonization to active disease, we subsequently focused our analysis on identifying differentially abundant species between the <italic>C. difficile</italic> asymptomatic carriage (AC) and infection (CDI) groups. Among these specific microbial candidates, <italic>O. splanchnicus</italic> was identified as a key species negatively correlated with disease severity. Notably, a recent study revealed a protective role for <italic>O. splanchnicus</italic> in inflammatory bowel disease (IBD), mediated through its involvement in the conversion of lithocholic acid (LCA), which helps alleviate colitis and maintain intestinal barrier integrity (<xref ref-type="bibr" rid="ref54">Xu et al., 2025</xref>). Given that CDI is primarily characterized by intestinal infection and barrier disruption, this established mechanism may, at least in part, explain the observed negative correlation between a high abundance of OS and milder CDI symptoms in our cohort. However, it has not been established whether <italic>O. splanchnicus</italic> has a direct inhibitory effect on <italic>C. difficile</italic>.</p>
<p>Several mechanisms of different bacteria for inhibiting <italic>C. difficile</italic> pathogenicity have been described. For instance, Kolling <italic>et al.</italic> demonstrated that <italic>Streptococcus thermophilus</italic> directly suppresses the growth of <italic>C. difficile</italic> as well as the TcdA toxin <italic>in vitro</italic> by secreting lactic acid, which exerts a dose-dependent bactericidal effect (<xref ref-type="bibr" rid="ref23">Kolling et al., 2012</xref>). Another study utilizing an automated anaerobic <italic>in vitro</italic> fermentor demonstrated that the supernatant of <italic>Clostridium scindens</italic> contains secreted factors which suppress the growth of <italic>C. difficile</italic> and the expression of its TcdA and TcdB toxins (<xref ref-type="bibr" rid="ref40">Saenz et al., 2023</xref>). In contrast to mechanisms centered on growth inhibition, our experimental results revealed that co-culture with <italic>O. splanchnicus</italic> did not significantly suppress the growth of <italic>C. difficile</italic>, which exhibited robust proliferation between 6 to 18&#x202F;h. This result was in line with a previous study which employed a culturomics approach to build a strain library for identifying <italic>C. difficile</italic>-inhibiting species (<xref ref-type="bibr" rid="ref14">Ghimire et al., 2020</xref>), and this research also isolated <italic>O. splanchnicus</italic> and similarly reported no inhibitory effect on <italic>C. difficile</italic> growth, aligning with our observation. Therefore, the combined evidence indicates that the mitigation of <italic>C. difficile</italic> pathogenicity by <italic>O. splanchnicus</italic> is not achieved through restraining the growth of vegetative cells.</p>
<p>We further demonstrated that <italic>O. splanchnicus</italic> suppresses <italic>C. difficile</italic> toxin production especially TcdB toxin in a time-dependent manner, with the effect being most pronounced at the highest initial <italic>O. splanchnicus</italic> ratio (CD: OS =&#x202F;1:9). The most significant reduction occurred during the stationary phase (48&#x2013;72&#x202F;h), which coincides with the peak toxin production in monoculture (<xref ref-type="bibr" rid="ref33">Metcalf et al., 2010</xref>). Concurrent qPCR analysis revealed that the suppression is initiated at the transcriptional level. A significant downregulation of <italic>tcdB</italic> expression was specifically observed at early and mid time points (12&#x2013;24&#x202F;h) in co-cultures with a high initial <italic>O. splanchnicus</italic> ratio. This early transcriptional inhibition provides a direct molecular explanation for the subsequent reduction in toxin protein levels detected later during the stationary phase. However, we found that toxin levels increased in both co-culture groups (CD: OS =&#x202F;1:1 and 9:1) at 72&#x202F;h, with the levels showing no statistically significant difference from the <italic>C. difficile</italic> monoculture. And this increase was accompanied by a significant upregulation of <italic>tcdB</italic> gene expression in the CD: OS =&#x202F;9:1 group. We propose that this late-stage resurgence of virulence is likely due to a decline in the metabolic activity of <italic>O. splanchnicus</italic> as the co-culture enters the late stationary phase. This dynamic aligns with the fundamental ecological principle that a commensal bacterium&#x2019;s protective function is closely linked to its abundance and activity within its niche (<xref ref-type="bibr" rid="ref1">Buffie et al., 2015</xref>; <xref ref-type="bibr" rid="ref3">Caballero-Flores et al., 2022</xref>). For instance, <italic>Clostridium scindens</italic> must reach a sufficient abundance to produce inhibitory secondary bile acids (<xref ref-type="bibr" rid="ref46">Studer et al., 2016</xref>). Similarly, <italic>O. splanchnicus</italic> likely requires a sustained level of metabolic activity to continuously suppress <italic>C. difficile</italic> toxin production, possibly via nutrient competition.</p>
<p>Concurrently, we observed a notable increase in <italic>C. difficile</italic> sporulation within the co-culture system, particularly evident at the 24-h time point. This phenotypic shift aligns with the well-established regulatory circuitry of <italic>C. difficile</italic>, where toxin production and sporulation are coordinately influenced by environmental cues such as nutrient availability (<xref ref-type="bibr" rid="ref29">Majumdar and Govind, 2022</xref>; <xref ref-type="bibr" rid="ref32">Masset et al., 2024</xref>). Co-culture with gut commensals can impose nutrient stress on <italic>C. difficile</italic>, and the consumption of preferred carbon and nitrogen sources by competitors can alter the metabolic environment, thereby accelerating spore formation (<xref ref-type="bibr" rid="ref47">Sulaiman et al., 2024</xref>; <xref ref-type="bibr" rid="ref10">Dong et al., 2025</xref>). Therefore, we proposed that <italic>O. splanchnicus</italic> may accelerate the transition of <italic>C. difficile</italic> vegetative cells into dormant spores, which consequently lead to the observed reduction in toxins production. However, both the sporulation-enhancing and toxin-suppressing effects exhibited dynamic changes over time. By the 72-h time point, the difference in spore counts between co-culture groups and the <italic>C. difficile</italic> monoculture was no longer statistically significant. We attribute this convergence, along with the late-stage rebound in toxin production noted earlier, primarily to a decline in the metabolic activity of <italic>O. splanchnicus</italic> as the co-culture enters the late stationary phase. This observation underscores that the anti-virulence effect of OS is not static but depends on its sustained metabolic activity within the ecological niche.</p>
<p>Simultaneously, the potential epidemiological implications of OS-enhanced <italic>C. difficile</italic> sporulation warrant careful consideration. From a transmission perspective, an increase in spore production could theoretically elevate the environmental persistence and spread of <italic>C. difficile</italic> within healthcare settings, as spores are the primary, highly resilient vector for dissemination (<xref ref-type="bibr" rid="ref30">Martin et al., 2016</xref>; <xref ref-type="bibr" rid="ref42">Schnizlein and Young, 2022</xref>). However, this potential risk must be evaluated within a more nuanced and holistic framework. Crucially, <italic>O. splanchnicus</italic> concurrently and significantly suppresses toxin production, which directly reduces disease severity and symptomatic diarrhea in the host. Since symptomatic diarrhea is the primary driver of infectious, spore-laden stool output, this reduction could substantially decrease the overall source of environmental contamination (<xref ref-type="bibr" rid="ref39">Riggs et al., 2007</xref>; <xref ref-type="bibr" rid="ref6">Crobach et al., 2018</xref>). Furthermore, our simplified <italic>in vitro</italic> model cannot replicate critical <italic>in vivo</italic> factors, such as intestinal peristalsis for physical clearance and a fully functional immune response that profoundly influence the actual shedding, survival, and ultimate transmission potential of spores. Therefore, future studies employing animal infection models and clinical observations are needed to evaluate the actual impact of <italic>O. splanchnicus</italic> supplementation on <italic>C. difficile</italic> colonization, recurrence, and environmental dissemination.</p>
<p>In summary, our studies suggest that <italic>O. splanchnicus</italic> plays a crucial role in mitigating <italic>C. difficile</italic> pathogenesis. We show that higher <italic>O. splanchnicus</italic> levels correlate with milder disease in patients and demonstrate in vitro that it suppresses <italic>C. difficile</italic> toxin production, particularly TcdB, while promoting sporulation at earlier stage. The identification of <italic>O. splanchnicus</italic> provides a novel and promising candidate for next-generation live biotherapeutics. Nevertheless, further studies are needed to define its precise mode of action and effective dose <italic>in vivo</italic> for therapeutic development.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec23">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: <ext-link xlink:href="https://www.cncb.ac.cn/" ext-link-type="uri">https://www.cncb.ac.cn/</ext-link>, PRJCA050088.</p>
</sec>
<sec sec-type="ethics-statement" id="sec24">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Clinical Research Ethical Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University (No. 2020-651). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec sec-type="author-contributions" id="sec25">
<title>Author contributions</title>
<p>NWa: Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. JF: Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. XG: Data curation, Writing &#x2013; review &#x0026; editing. SZ: Writing &#x2013; review &#x0026; editing, Data curation. ZP: Writing &#x2013; review &#x0026; editing, Methodology, Data curation. CJ: Conceptualization, Writing &#x2013; review &#x0026; editing, Supervision. YC: Funding acquisition, Writing &#x2013; review &#x0026; editing, Resources, Supervision. NWu: Supervision, Writing &#x2013; review &#x0026; editing, Project administration.</p>
</sec>
<sec sec-type="COI-statement" id="sec26">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec27">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec28">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec29">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2026.1741232/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmicb.2026.1741232/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffie</surname> <given-names>C. G.</given-names></name> <name><surname>Bucci</surname> <given-names>V.</given-names></name> <name><surname>Stein</surname> <given-names>R. R.</given-names></name> <name><surname>McKenney</surname> <given-names>P. T.</given-names></name> <name><surname>Ling</surname> <given-names>L.</given-names></name> <name><surname>Gobourne</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Precision microbiome reconstitution restores bile acid mediated resistance to <italic>Clostridium difficile</italic></article-title>. <source>Nature</source> <volume>517</volume>, <fpage>205</fpage>&#x2013;<lpage>208</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature13828</pub-id>, <pub-id pub-id-type="pmid">25337874</pub-id></mixed-citation></ref>
<ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname> <given-names>S.</given-names></name> <name><surname>Kim</surname> <given-names>S.</given-names></name> <name><surname>Carter</surname> <given-names>R. A.</given-names></name> <name><surname>Leiner</surname> <given-names>I. M.</given-names></name> <name><surname>Susac</surname> <given-names>B.</given-names></name> <name><surname>Miller</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Cooperating commensals restore colonization resistance to vancomycin-resistant <italic>Enterococcus faecium</italic></article-title>. <source>Cell Host Microbe</source> <volume>21</volume>, <fpage>592</fpage>&#x2013;<lpage>602.e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2017.04.002</pub-id>, <pub-id pub-id-type="pmid">28494240</pub-id></mixed-citation></ref>
<ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero-Flores</surname> <given-names>G.</given-names></name> <name><surname>Pickard</surname> <given-names>J. M.</given-names></name> <name><surname>Nunez</surname> <given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>Microbiota-mediated colonization resistance: mechanisms and regulation</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>21</volume>, <fpage>347</fpage>&#x2013;<lpage>360</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-022-00833-7</pub-id>, <pub-id pub-id-type="pmid">36539611</pub-id></mixed-citation></ref>
<ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname> <given-names>B. J.</given-names></name> <name><surname>McMurdie</surname> <given-names>P. J.</given-names></name> <name><surname>Rosen</surname> <given-names>M. J.</given-names></name> <name><surname>Han</surname> <given-names>A. W.</given-names></name> <name><surname>Johnson</surname> <given-names>A. J. A.</given-names></name> <name><surname>Holmes</surname> <given-names>S. P.</given-names></name></person-group> (<year>2016</year>). <article-title>DADA2: high-resolution sample inference from Illumina amplicon data</article-title>. <source>Nat. Methods</source> <volume>13</volume>, <fpage>581</fpage>&#x2013;<lpage>583</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nmeth.3869</pub-id>, <pub-id pub-id-type="pmid">27214047</pub-id></mixed-citation></ref>
<ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couturier</surname> <given-names>J.</given-names></name> <name><surname>Lepage</surname> <given-names>P.</given-names></name> <name><surname>Jolivet</surname> <given-names>S.</given-names></name> <name><surname>Delannoy</surname> <given-names>J.</given-names></name> <name><surname>Mesa</surname> <given-names>V.</given-names></name> <name><surname>Ancel</surname> <given-names>P.-Y.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Gut microbiota diversity of preterm neonates is associated with Clostridioides difficile colonization</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>12</volume>:<fpage>907323</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2022.907323</pub-id>, <pub-id pub-id-type="pmid">35873148</pub-id></mixed-citation></ref>
<ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crobach</surname> <given-names>M. J.</given-names></name> <name><surname>Vernon</surname> <given-names>J. J.</given-names></name> <name><surname>Loo</surname> <given-names>V. G.</given-names></name> <name><surname>Kong</surname> <given-names>L. Y.</given-names></name> <name><surname>P&#x00E9;chin&#x00E9;</surname> <given-names>S.</given-names></name> <name><surname>Wilcox</surname> <given-names>M. H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Understanding <italic>Clostridium difficile</italic> colonization</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>31</volume>:<fpage>e00021-17</fpage>. doi: <pub-id pub-id-type="doi">10.1128/cmr.00021-17</pub-id></mixed-citation></ref>
<ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFilipp</surname> <given-names>Z.</given-names></name> <name><surname>Bloom</surname> <given-names>P. P.</given-names></name> <name><surname>Torres Soto</surname> <given-names>M.</given-names></name> <name><surname>Mansour</surname> <given-names>M. K.</given-names></name> <name><surname>Sater</surname> <given-names>M. R. A.</given-names></name> <name><surname>Huntley</surname> <given-names>M. H.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Drug-Resistant <italic>E. coli</italic> bacteremia transmitted by fecal microbiota transplant</article-title>. <source>N. Engl. J. Med.</source> <volume>381</volume>, <fpage>2043</fpage>&#x2013;<lpage>2050</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1910437</pub-id>, <pub-id pub-id-type="pmid">31665575</pub-id></mixed-citation></ref>
<ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLeon</surname> <given-names>O.</given-names></name> <name><surname>Mocanu</surname> <given-names>M.</given-names></name> <name><surname>Tan</surname> <given-names>A.</given-names></name> <name><surname>Sidebottom</surname> <given-names>A. M.</given-names></name> <name><surname>Koval</surname> <given-names>J.</given-names></name> <name><surname>Ceccato</surname> <given-names>H. D.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effects</article-title>. <source>Cell</source> <volume>188</volume>, <fpage>3927</fpage>&#x2013;<lpage>3941.e13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2025.05.014</pub-id>, <pub-id pub-id-type="pmid">40482640</pub-id></mixed-citation></ref>
<ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname> <given-names>Y.</given-names></name> <name><surname>Jiang</surname> <given-names>Y.-H.</given-names></name> <name><surname>Yang</surname> <given-names>Y.</given-names></name> <name><surname>He</surname> <given-names>Z.</given-names></name> <name><surname>Luo</surname> <given-names>F.</given-names></name> <name><surname>Zhou</surname> <given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Molecular ecological network analyses</article-title>. <source>BMC Bioinformatics</source> <volume>13</volume>:<fpage>113</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-13-113</pub-id>, <pub-id pub-id-type="pmid">22646978</pub-id></mixed-citation></ref>
<ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>Q.</given-names></name> <name><surname>Harper</surname> <given-names>S.</given-names></name> <name><surname>McSpadden</surname> <given-names>E.</given-names></name> <name><surname>Son</surname> <given-names>S. S.</given-names></name> <name><surname>Allen</surname> <given-names>M.-M.</given-names></name> <name><surname>Lin</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Protection against Clostridioides difficile disease by a naturally avirulent strain</article-title>. <source>Cell Host Microbe</source> <volume>33</volume>, <fpage>59</fpage>&#x2013;<lpage>70.e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2024.11.003</pub-id>, <pub-id pub-id-type="pmid">39610252</pub-id></mixed-citation></ref>
<ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname> <given-names>M. L.</given-names></name> <name><surname>Shrestha</surname> <given-names>S.</given-names></name> <name><surname>Ribis John</surname> <given-names>W.</given-names></name> <name><surname>Kuhn</surname> <given-names>P.</given-names></name> <name><surname>Krasilnikov</surname> <given-names>M.</given-names></name> <name><surname>Alves Feliciano</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Development of a dual-fluorescent-reporter system in <italic>Clostridioides difficile</italic> reveals a division of labor between virulence and transmission gene expression</article-title>. <source>mSphere</source> <volume>7</volume>:<fpage>e00132-00122</fpage>. doi: <pub-id pub-id-type="doi">10.1128/msphere.00132-22</pub-id></mixed-citation></ref>
<ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname> <given-names>A. N.</given-names></name> <name><surname>McBride</surname> <given-names>S. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Initiation of sporulation in <italic>Clostridium difficile</italic>: a twist on the classic model</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>358</volume>, <fpage>110</fpage>&#x2013;<lpage>118</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1574-6968.12499</pub-id>, <pub-id pub-id-type="pmid">24910370</pub-id></mixed-citation></ref>
<ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname> <given-names>E.</given-names></name> <name><surname>Andersson</surname> <given-names>F. L.</given-names></name> <name><surname>Madin-Warburton</surname> <given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Burden of Clostridioides difficile infection (CDI)-a systematic review of the epidemiology of primary and recurrent CDI</article-title>. <source>BMC Infect. Dis.</source> <volume>21</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-021-06147-y</pub-id></mixed-citation></ref>
<ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghimire</surname> <given-names>S.</given-names></name> <name><surname>Roy</surname> <given-names>C.</given-names></name> <name><surname>Wongkuna</surname> <given-names>S.</given-names></name> <name><surname>Antony</surname> <given-names>L.</given-names></name> <name><surname>Maji</surname> <given-names>A.</given-names></name> <name><surname>Keena</surname> <given-names>M. C.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Identification of <italic>Clostridioides difficile</italic>-inhibiting gut commensals using culturomics, phenotyping, and combinatorial community assembly</article-title>. <source>mSystems</source> <volume>5</volume>:<fpage>e00620-00619</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mSystems.00620-19</pub-id></mixed-citation></ref>
<ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>A.</given-names></name> <name><surname>Cifu</surname> <given-names>A. S.</given-names></name> <name><surname>Khanna</surname> <given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Diagnosis and treatment of <italic>Clostridium difficile</italic> infection</article-title>. <source>JAMA</source> <volume>320</volume>, <fpage>1031</fpage>&#x2013;<lpage>1032</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2018.12194</pub-id>, <pub-id pub-id-type="pmid">30178042</pub-id></mixed-citation></ref>
<ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henson</surname> <given-names>M. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection</article-title>. <source>PLoS Comput. Biol.</source> <volume>17</volume>:<fpage>e1008782</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pcbi.1008782</pub-id>, <pub-id pub-id-type="pmid">33617526</pub-id></mixed-citation></ref>
<ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname> <given-names>G.</given-names></name> <name><surname>Arboleda</surname> <given-names>J. C.</given-names></name> <name><surname>P&#x00E9;rez-Jaramillo</surname> <given-names>J. E.</given-names></name> <name><surname>Patarroyo</surname> <given-names>M. A.</given-names></name> <name><surname>Ram&#x00ED;rez</surname> <given-names>J. D.</given-names></name> <name><surname>Mu&#x00F1;oz</surname> <given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Microbial Interdomain interactions delineate the disruptive intestinal homeostasis in Clostridioides difficile infection</article-title>. <source>Microbiol. Spectr.</source> <volume>10</volume>, <fpage>e00502</fpage>&#x2013;<lpage>e00522</lpage>. doi: <pub-id pub-id-type="doi">10.1128/spectrum.00502-22</pub-id></mixed-citation></ref>
<ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname> <given-names>L. E.</given-names></name> <name><surname>Anderson</surname> <given-names>S. E.</given-names></name> <name><surname>Corbett</surname> <given-names>A. H.</given-names></name> <name><surname>Lamb</surname> <given-names>T. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational Design of Combination Microbial Therapies</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>30</volume>, <fpage>191</fpage>&#x2013;<lpage>231</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00049-16</pub-id>, <pub-id pub-id-type="pmid">27856521</pub-id></mixed-citation></ref>
<ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachrimanidou</surname> <given-names>M.</given-names></name> <name><surname>Tsintarakis</surname> <given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Insights into the role of human gut microbiota in Clostridioides difficile infection</article-title>. <source>Microorganisms</source> <volume>8</volume>:<fpage>200</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms8020200</pub-id>, <pub-id pub-id-type="pmid">32023967</pub-id></mixed-citation></ref>
<ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname> <given-names>S.</given-names></name> <name><surname>Pollock</surname> <given-names>N. R.</given-names></name> <name><surname>Wang</surname> <given-names>X. W.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <name><surname>Daugherty</surname> <given-names>K.</given-names></name> <name><surname>Lin</surname> <given-names>Q.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection</article-title>. <source>Gut Microbes</source> <volume>13</volume>, <fpage>1</fpage>&#x2013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2021.1935186</pub-id>, <pub-id pub-id-type="pmid">34132169</pub-id></mixed-citation></ref>
<ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname> <given-names>C. R.</given-names></name> <name><surname>Yen</surname> <given-names>E. F.</given-names></name> <name><surname>Grinspan</surname> <given-names>A. M.</given-names></name> <name><surname>Kahn</surname> <given-names>S. A.</given-names></name> <name><surname>Atreja</surname> <given-names>A.</given-names></name> <name><surname>Lewis</surname> <given-names>J. D.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT National Registry</article-title>. <source>Gastroenterology</source> <volume>160</volume>, <fpage>183</fpage>&#x2013;<lpage>192.e3</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2020.09.038</pub-id>, <pub-id pub-id-type="pmid">33011173</pub-id></mixed-citation></ref>
<ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoruts</surname> <given-names>A.</given-names></name> <name><surname>Staley</surname> <given-names>C.</given-names></name></person-group> (<year>2025</year>). <article-title>Fmt for recurrent <italic>Clostridioides difficile</italic> infection</article-title>. <source>Clin. Infect. Dis.</source> <volume>81</volume>:<fpage>e59-e59</fpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciaf138</pub-id></mixed-citation></ref>
<ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolling</surname> <given-names>G. L.</given-names></name> <name><surname>Wu</surname> <given-names>M.</given-names></name> <name><surname>Warren</surname> <given-names>C. A.</given-names></name> <name><surname>Durmaz</surname> <given-names>E.</given-names></name> <name><surname>Klaenhammer</surname> <given-names>T. R.</given-names></name> <name><surname>Timko</surname> <given-names>M. P.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Lactic acid production by <italic>Streptococcus thermophilus</italic> alters <italic>Clostridium difficile</italic> infection and in vitro toxin a production</article-title>. <source>Gut Microbes</source> <volume>3</volume>, <fpage>523</fpage>&#x2013;<lpage>529</lpage>. doi: <pub-id pub-id-type="doi">10.4161/gmic.21757</pub-id></mixed-citation></ref>
<ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kordus</surname> <given-names>S. L.</given-names></name> <name><surname>Thomas</surname> <given-names>A. K.</given-names></name> <name><surname>Lacy</surname> <given-names>D. B.</given-names></name></person-group> (<year>2022</year>). <article-title>Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>20</volume>, <fpage>285</fpage>&#x2013;<lpage>298</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-021-00660-2</pub-id>, <pub-id pub-id-type="pmid">34837014</pub-id></mixed-citation></ref>
<ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Xu</surname> <given-names>J.</given-names></name> <name><surname>Guo</surname> <given-names>X.</given-names></name> <name><surname>Xu</surname> <given-names>H.</given-names></name> <name><surname>Huang</surname> <given-names>C.</given-names></name> <name><surname>Nie</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title><italic>Odoribacter splanchnicus</italic>&#x2014;a next-generation probiotic candidate</article-title>. <source>Microorganisms</source> <volume>13</volume>:<fpage>815</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms13040815</pub-id></mixed-citation></ref>
<ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname> <given-names>K. J.</given-names></name> <name><surname>Schmittgen</surname> <given-names>T. D.</given-names></name></person-group> (<year>2001</year>). <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>&#x2212;&#x0394;&#x0394;CT</sup> method</article-title>. <source>Methods</source> <volume>25</volume>, <fpage>402</fpage>&#x2013;<lpage>408</lpage>. doi: <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></mixed-citation></ref>
<ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maestri</surname> <given-names>A. C.</given-names></name> <name><surname>Raboni</surname> <given-names>S. M.</given-names></name> <name><surname>Cogo</surname> <given-names>L. L.</given-names></name> <name><surname>Rossi</surname> <given-names>M. V.</given-names></name> <name><surname>Nogueira</surname> <given-names>K. S.</given-names></name></person-group> (<year>2022</year>). <article-title>Standardisation and validation of an in-house quantitative real-time polymerase chain reaction (qPCR) assay for the diagnosis of <italic>Clostridioides difficile</italic> infection</article-title>. <source>J. Microbiol. Methods</source> <volume>193</volume>:<fpage>106399</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mimet.2021.106399</pub-id>, <pub-id pub-id-type="pmid">34958834</pub-id></mixed-citation></ref>
<ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahnic</surname> <given-names>A.</given-names></name> <name><surname>Pintar</surname> <given-names>S.</given-names></name> <name><surname>Skok</surname> <given-names>P.</given-names></name> <name><surname>Rupnik</surname> <given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Gut community alterations associated with Clostridioides difficile colonization in hospitalized gastroenterological patients with or without inflammatory bowel disease</article-title>. <source>Front. Microbiol.</source> <volume>13</volume>:<fpage>988426</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2022.988426</pub-id>, <pub-id pub-id-type="pmid">36147861</pub-id></mixed-citation></ref>
<ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumdar</surname> <given-names>A.</given-names></name> <name><surname>Govind</surname> <given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>Regulation of Clostridioides difficile toxin production</article-title>. <source>Curr. Opin. Microbiol.</source> <volume>65</volume>, <fpage>95</fpage>&#x2013;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mib.2021.10.018</pub-id>, <pub-id pub-id-type="pmid">34781095</pub-id></mixed-citation></ref>
<ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>J. S.</given-names></name> <name><surname>Monaghan</surname> <given-names>T. M.</given-names></name> <name><surname>Wilcox</surname> <given-names>M. H.</given-names></name></person-group> (<year>2016</year>). <article-title><italic>Clostridium difficile</italic> infection: epidemiology, diagnosis and understanding transmission</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>13</volume>, <fpage>206</fpage>&#x2013;<lpage>216</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2016.25</pub-id>, <pub-id pub-id-type="pmid">26956066</pub-id></mixed-citation></ref>
<ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname> <given-names>E.</given-names></name> <name><surname>Taminiau</surname> <given-names>B.</given-names></name> <name><surname>Rodriguez</surname> <given-names>C.</given-names></name> <name><surname>Daube</surname> <given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>Gut microbiota composition associated with <italic>Clostridioides difficile</italic> colonization and infection</article-title>. <source>Pathogens</source> <volume>11</volume>:<fpage>781</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens11070781</pub-id>, <pub-id pub-id-type="pmid">35890026</pub-id></mixed-citation></ref>
<ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masset</surname> <given-names>Z.</given-names></name> <name><surname>Gunaratnam</surname> <given-names>S.</given-names></name> <name><surname>Millette</surname> <given-names>M.</given-names></name> <name><surname>McFarland</surname> <given-names>L. V.</given-names></name> <name><surname>Lacroix</surname> <given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>Environmental and nutritional parameters modulating genetic expression for virulence factors of <italic>Clostridioides difficile</italic></article-title>. <source>Antibiotics</source> <volume>13</volume>:<fpage>365</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics13040365</pub-id>, <pub-id pub-id-type="pmid">38667041</pub-id></mixed-citation></ref>
<ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metcalf</surname> <given-names>D.</given-names></name> <name><surname>Sharif</surname> <given-names>S.</given-names></name> <name><surname>Weese</surname> <given-names>J. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Evaluation of candidate reference genes in <italic>Clostridium difficile</italic> for gene expression normalization</article-title>. <source>Anaerobe</source> <volume>16</volume>, <fpage>439</fpage>&#x2013;<lpage>443</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.anaerobe.2010.06.007</pub-id>, <pub-id pub-id-type="pmid">20599622</pub-id></mixed-citation></ref>
<ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulki</surname> <given-names>R.</given-names></name> <name><surname>Baumann</surname> <given-names>A.</given-names></name> <name><surname>Alnabelsi</surname> <given-names>T.</given-names></name> <name><surname>Sandhu</surname> <given-names>N.</given-names></name> <name><surname>Alhamshari</surname> <given-names>Y.</given-names></name> <name><surname>Wheeler</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Body mass index greater than 35 is associated with severe <italic>Clostridium difficile</italic> infection</article-title>. <source>Aliment. Pharmacol. Ther.</source> <volume>45</volume>, <fpage>75</fpage>&#x2013;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1111/apt.13832</pub-id>, <pub-id pub-id-type="pmid">27790736</pub-id></mixed-citation></ref>
<ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>C. K.</given-names></name> <name><surname>O&#x2019;Donnell</surname> <given-names>M. M.</given-names></name> <name><surname>Hegarty</surname> <given-names>J. W.</given-names></name> <name><surname>Schulz</surname> <given-names>S.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name> <name><surname>Ross</surname> <given-names>R. P.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo</article-title>. <source>World J. Gastrointest. Pathophysiol.</source> <volume>14</volume>:<fpage>71</fpage>. doi: <pub-id pub-id-type="doi">10.4291/wjgp.v14.i4.71</pub-id></mixed-citation></ref>
<ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ofosu</surname> <given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title><italic>Clostridium difficile</italic> infection: a review of current and emerging therapies</article-title>. <source>Ann. Gastroenterol.</source> <volume>29</volume>:<fpage>147</fpage>. doi: <pub-id pub-id-type="doi">10.20524/aog.2016.0006</pub-id>, <pub-id pub-id-type="pmid">27065726</pub-id></mixed-citation></ref>
<ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peretz</surname> <given-names>A.</given-names></name> <name><surname>Tkhawkho</surname> <given-names>L.</given-names></name> <name><surname>Pastukh</surname> <given-names>N.</given-names></name> <name><surname>Brodsky</surname> <given-names>D.</given-names></name> <name><surname>Halevi</surname> <given-names>C. N.</given-names></name> <name><surname>Nitzan</surname> <given-names>O.</given-names></name></person-group> (<year>2016</year>). <article-title>Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with <italic>Clostridium difficile</italic> infection</article-title>. <source>BMC Infect. Dis.</source> <volume>16</volume>:<fpage>309</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-016-1618-8</pub-id>, <pub-id pub-id-type="pmid">27334992</pub-id></mixed-citation></ref>
<ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccioni</surname> <given-names>A.</given-names></name> <name><surname>Rosa</surname> <given-names>F.</given-names></name> <name><surname>Manca</surname> <given-names>F.</given-names></name> <name><surname>Pignataro</surname> <given-names>G.</given-names></name> <name><surname>Zanza</surname> <given-names>C.</given-names></name> <name><surname>Savioli</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Gut microbiota and <italic>clostridium difficile</italic>: what we know and the new frontiers</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>:<fpage>13323</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms232113323</pub-id></mixed-citation></ref>
<ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname> <given-names>M. M.</given-names></name> <name><surname>Sethi</surname> <given-names>A. K.</given-names></name> <name><surname>Zabarsky</surname> <given-names>T. F.</given-names></name> <name><surname>Eckstein</surname> <given-names>E. C.</given-names></name> <name><surname>Jump</surname> <given-names>R. L.</given-names></name> <name><surname>Donskey</surname> <given-names>C. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic <italic>Clostridium difficile</italic> strains among long-term care facility residents</article-title>. <source>Clin. Infect. Dis.</source> <volume>45</volume>, <fpage>992</fpage>&#x2013;<lpage>998</lpage>. doi: <pub-id pub-id-type="doi">10.1086/521854</pub-id></mixed-citation></ref>
<ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saenz</surname> <given-names>C.</given-names></name> <name><surname>Fang</surname> <given-names>Q.</given-names></name> <name><surname>Gnanasekaran</surname> <given-names>T.</given-names></name> <name><surname>Trammell Samuel Addison</surname> <given-names>J.</given-names></name> <name><surname>Buijink Jesse</surname> <given-names>A.</given-names></name> <name><surname>Pisano</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title><italic>Clostridium scindens</italic> secretome suppresses virulence gene expression of Clostridioides difficile in a bile acid-independent manner</article-title>. <source>Microbiol. Spectr.</source> <volume>11</volume>:<fpage>e03933-03922</fpage>. doi: <pub-id pub-id-type="doi">10.1128/spectrum.03933-22</pub-id></mixed-citation></ref>
<ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>Y.</given-names></name> <name><surname>Atarashi</surname> <given-names>K.</given-names></name> <name><surname>Plichta</surname> <given-names>D. R.</given-names></name> <name><surname>Arai</surname> <given-names>Y.</given-names></name> <name><surname>Sasajima</surname> <given-names>S.</given-names></name> <name><surname>Kearney</surname> <given-names>S. M.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians</article-title>. <source>Nature</source> <volume>599</volume>, <fpage>458</fpage>&#x2013;<lpage>464</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-021-03832-5</pub-id>, <pub-id pub-id-type="pmid">34325466</pub-id></mixed-citation></ref>
<ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnizlein</surname> <given-names>M. K.</given-names></name> <name><surname>Young</surname> <given-names>V. B.</given-names></name></person-group> (<year>2022</year>). <article-title>Capturing the environment of the Clostridioides difficile infection cycle</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>19</volume>, <fpage>508</fpage>&#x2013;<lpage>520</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41575-022-00610-0</pub-id>, <pub-id pub-id-type="pmid">35468953</pub-id></mixed-citation></ref>
<ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shade</surname> <given-names>A.</given-names></name> <name><surname>Handelsman</surname> <given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Beyond the Venn diagram: the hunt for a core microbiome</article-title>. <source>Environ. Microbiol.</source> <volume>14</volume>, <fpage>4</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1462-2920.2011.02585.x</pub-id>, <pub-id pub-id-type="pmid">22004523</pub-id></mixed-citation></ref>
<ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>A. B.</given-names></name> <name><surname>Jenior</surname> <given-names>M. L.</given-names></name> <name><surname>Keenan</surname> <given-names>O.</given-names></name> <name><surname>Hart</surname> <given-names>J. L.</given-names></name> <name><surname>Specker</surname> <given-names>J.</given-names></name> <name><surname>Abbas</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Enterococci enhance Clostridioides difficile pathogenesis</article-title>. <source>Nature</source> <volume>611</volume>, <fpage>780</fpage>&#x2013;<lpage>786</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-022-05438-x</pub-id>, <pub-id pub-id-type="pmid">36385534</pub-id></mixed-citation></ref>
<ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname> <given-names>W. K.</given-names></name> <name><surname>Lyras</surname> <given-names>D.</given-names></name> <name><surname>Lacy</surname> <given-names>D. B.</given-names></name> <name><surname>Wilcox</surname> <given-names>M. H.</given-names></name> <name><surname>Kuijper</surname> <given-names>E. J.</given-names></name></person-group> (<year>2016</year>). <article-title><italic>Clostridium difficile</italic> infection</article-title>. <source>Nat. Rev. Dis. Prim.</source> <volume>2</volume>:<fpage>16020</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2016.20</pub-id>, <pub-id pub-id-type="pmid">27158839</pub-id></mixed-citation></ref>
<ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studer</surname> <given-names>N.</given-names></name> <name><surname>Desharnais</surname> <given-names>L.</given-names></name> <name><surname>Beutler</surname> <given-names>M.</given-names></name> <name><surname>Brugiroux</surname> <given-names>S.</given-names></name> <name><surname>Terrazos</surname> <given-names>M. A.</given-names></name> <name><surname>Menin</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Functional intestinal bile acid 7&#x03B1;-Dehydroxylation by <italic>Clostridium scindens</italic> associated with protection from <italic>Clostridium difficile</italic> infection in a Gnotobiotic mouse model</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>6</volume>:<fpage>191</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2016.00191</pub-id>, <pub-id pub-id-type="pmid">28066726</pub-id></mixed-citation></ref>
<ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulaiman</surname> <given-names>J. E.</given-names></name> <name><surname>Thompson</surname> <given-names>J.</given-names></name> <name><surname>Qian</surname> <given-names>Y.</given-names></name> <name><surname>Vivas</surname> <given-names>E. I.</given-names></name> <name><surname>Diener</surname> <given-names>C.</given-names></name> <name><surname>Gibbons</surname> <given-names>S. M.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Elucidating human gut microbiota interactions that robustly inhibit diverse Clostridioides difficile strains across different nutrient landscapes</article-title>. <source>Nat. Commun.</source> <volume>15</volume>:<fpage>7416</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-024-51062-w</pub-id>, <pub-id pub-id-type="pmid">39198411</pub-id></mixed-citation></ref>
<ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trzilova</surname> <given-names>D.</given-names></name> <name><surname>Warren</surname> <given-names>M. A. H.</given-names></name> <name><surname>Gadda</surname> <given-names>N. C.</given-names></name> <name><surname>Williams</surname> <given-names>C. L.</given-names></name> <name><surname>Tamayo</surname> <given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>Flagellum and toxin phase variation impacts intestinal colonization and disease development in a mouse model of Clostridioides difficile infection</article-title>. <source>Gut Microbes</source> <volume>14</volume>:<fpage>2038854</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2022.2038854</pub-id>, <pub-id pub-id-type="pmid">35192433</pub-id></mixed-citation></ref>
<ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakili</surname> <given-names>B.</given-names></name> <name><surname>Fateh</surname> <given-names>A.</given-names></name> <name><surname>Asadzadeh Aghdaei</surname> <given-names>H.</given-names></name> <name><surname>Sotoodehnejadnematalahi</surname> <given-names>F.</given-names></name> <name><surname>Siadat</surname> <given-names>S. D.</given-names></name></person-group> (<year>2020</year>). <article-title>Intestinal microbiota in elderly inpatients with Clostridioides difficile infection</article-title>. <source>Infect. Drug Resist.</source> <volume>13</volume>, <fpage>2723</fpage>&#x2013;<lpage>2731</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S262019</pub-id>, <pub-id pub-id-type="pmid">32801806</pub-id></mixed-citation></ref>
<ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x00E1;zquez-Cuesta</surname> <given-names>S.</given-names></name> <name><surname>Villar</surname> <given-names>L.</given-names></name> <name><surname>Garc&#x00ED;a</surname> <given-names>N. L.</given-names></name> <name><surname>Fern&#x00E1;ndez</surname> <given-names>A. I.</given-names></name> <name><surname>Olmedo</surname> <given-names>M.</given-names></name> <name><surname>Alcal&#x00E1;</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non&#x2013;<italic>C. difficile</italic> diarrhea, and <italic>C. difficile</italic>&#x2013;colonized patients</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>13</volume>:<fpage>1130701</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2023.1130701</pub-id>, <pub-id pub-id-type="pmid">37124040</pub-id></mixed-citation></ref>
<ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voth</surname> <given-names>D. E.</given-names></name> <name><surname>Ballard</surname> <given-names>J. D.</given-names></name></person-group> (<year>2005</year>). <article-title><italic>Clostridium difficile</italic> toxins: mechanism of action and role in disease</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>18</volume>, <fpage>247</fpage>&#x2013;<lpage>263</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.18.2.247-263.2005</pub-id>, <pub-id pub-id-type="pmid">15831824</pub-id></mixed-citation></ref>
<ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>He</surname> <given-names>W.</given-names></name> <name><surname>Tian</surname> <given-names>Z.</given-names></name> <name><surname>Lin</surname> <given-names>J.</given-names></name> <name><surname>Liu</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Gut microbiota and metabolite changes in patients with ulcerative colitis and Clostridioides difficile infection</article-title>. <source>Front. Microbiol.</source> <volume>13</volume>:<fpage>802823</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2022.802823</pub-id>, <pub-id pub-id-type="pmid">35756051</pub-id></mixed-citation></ref>
<ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>S.</given-names></name> <name><surname>Bahl</surname> <given-names>M. I.</given-names></name> <name><surname>Baunwall</surname> <given-names>S. M. D.</given-names></name> <name><surname>Dahlerup</surname> <given-names>J. F.</given-names></name> <name><surname>Hvas</surname> <given-names>C. L.</given-names></name> <name><surname>Licht</surname> <given-names>T. R.</given-names></name></person-group> (<year>2022</year>). <article-title>Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection</article-title>. <source>Gut Microbes</source> <volume>14</volume>:<fpage>2084306</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2022.2084306</pub-id>, <pub-id pub-id-type="pmid">36519447</pub-id></mixed-citation></ref>
<ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>J.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Guo</surname> <given-names>X.</given-names></name> <name><surname>Huang</surname> <given-names>C.</given-names></name> <name><surname>Peng</surname> <given-names>Y.</given-names></name> <name><surname>Xu</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Secondary bile acids modified by <italic>Odoribacter Splanchnicus</italic> alleviate colitis by suppressing neutrophil extracellular trap formation. <italic>Advanced</italic></article-title>. <source>Science</source> <volume>12</volume>:<fpage>e09073</fpage>. doi: <pub-id pub-id-type="doi">10.1002/advs.202509073</pub-id></mixed-citation></ref>
<ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadegar</surname> <given-names>A.</given-names></name> <name><surname>Bar-Yoseph</surname> <given-names>H.</given-names></name> <name><surname>Monaghan</surname> <given-names>T. M.</given-names></name> <name><surname>Pakpour</surname> <given-names>S.</given-names></name> <name><surname>Severino</surname> <given-names>A.</given-names></name> <name><surname>Kuijper</surname> <given-names>E. J.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Fecal microbiota transplantation: current challenges and future landscapes</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>37</volume>, <fpage>e0006022</fpage>&#x2013;<lpage>e0000022</lpage>. doi: <pub-id pub-id-type="doi">10.1128/cmr.00060-22</pub-id>, <pub-id pub-id-type="pmid">38717124</pub-id></mixed-citation></ref>
<ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>D.</given-names></name> <name><surname>Wang</surname> <given-names>S.</given-names></name> <name><surname>Sun</surname> <given-names>X.</given-names></name></person-group> (<year>2021</year>). <article-title>FliW and CsrA govern Flagellin (FliC) synthesis and play pleiotropic roles in virulence and physiology of Clostridioides difficile R20291</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>:<fpage>735616</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2021.735616</pub-id>, <pub-id pub-id-type="pmid">34675903</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0002">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/457825/overview">Amit Ranjan</ext-link>, Columbia University, United States</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0003">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1736241/overview">Jos Van Der Vossen</ext-link>, Netherlands Organisation for Applied Scientific Research, Netherlands</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3285571/overview">Kannan Balakrishnan</ext-link>, Lerner Research Institute, United States</p>
</fn>
</fn-group>
</back>
</article>